Scientific methodology and practical use of managed entry agreements for innovative medicines in system of health technology assessment in Ukraine

Scientific methodology and practical use of managed entry agreements for innovative medicines in system of health technology assessment in Ukraine

In the Health Technology Assessment (HTA) system, it is advisable to use a mini-HTA to save budget funds at the hospital level, taking into account real world data on drug consumption for a rational use of resources at the local level. HTA include Managed Entry Agreements (MEA), which is being activ...

Full description

Bibliographic Details
Main Authors:	O. M. Zaliska, KH.-O. J. Stasiv
Format:	Article
Language:	Ukrainian
Published:	The State Expert Center of the Ministry of Health of Ukraine 2019-09-01
Series:	Фармацевтичний журнал
Subjects:	Health Technology Assessment mini-HTA assisted reproductive technologies Managed Entry Agreements innovative medicines
Online Access:	https://pharmj.org.ua/index.php/journal/article/view/616/579

Similar Items

Analysis of costs and results of assisted reproductive technologies in the world and Ukraine
by: Kh.-O. J. Stasiv, et al.
Published: (2018-08-01)

The value-for-money assessment and funding arrangements for high-priced drugs in an era of uncertainty: a comparative analysis of national health technology assessment agencies in South Korea, England, Australia, and Canada
by: Jihyung Hong, et al.
Published: (2025-01-01)

Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countries
by: Olina Efthymiadou, et al.
Published: (2022-08-01)

International experience of using report forms for hospital-based health technology asssessment
by: О. M. Filiniuk, et al.
Published: (2023-02-01)

Introduction of managed entry agreements in Korea: Problem, policy, and politics
by: Hyungmin Kim, et al.
Published: (2023-04-01)

KESELAMATAN KERJA PADA BONGKAR MUAT KAPAL MINI PURSE SEINE 10 GT DI PELABUHAN PERIKANAN LEMPASING
by: Lilis Nurbaiti, et al.
Published: (2023-05-01)

Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies
by: Pascale Lehoux, et al.
Published: (2017-09-01)

Organizational structure and funding of health technology assessment agencies around the world
by: G. R. Khachatryan, et al.
Published: (2019-07-01)

A roadmap toward implementing health technology assessment in Egypt
by: Ahmad Nader Fasseeh, et al.
Published: (2022-12-01)

Technology Assessment vs. Technology Appraisal—How to Strengthen the Science/Value Dichotomy with EU HTA?
by: Sandro Gsteiger, et al.
Published: (2024-11-01)

RELEVANCE OF THE USE OF ASSISTED REPRODUCTIVE TECHNOLOGIES IN CURRENT CONDITIONS IN UKRAINE
by: L.A. Lytvynova, et al.
Published: (2023-06-01)

EU HTA Regulation and Joint Clinical Assessment—Threat or Opportunity?
by: Volker Schuster
Published: (2024-05-01)

CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value’s Worth
by: Pierre J. A. Villeneuve, et al.
Published: (2023-04-01)

Evaluation of the Overall Quality of the Health Technology Assessment Educational Program from the Perspectives of University Professors and Learners in Iran
by: Ahmad Tahmasebi-Ghorrabi, et al.
Published: (2023-07-01)

Analysis of heterogeneity of the different health technology assessment reports produced on the transcatheter aortic valve implantation in patients with severe aortic valve stenosis at low surgical risk
by: Filippo Rumi, et al.
Published: (2023-08-01)

Do Health Technology Assessment organisations consider manufacturers’ costs in relation to drug price? A study of reimbursement reports
by: Joost J. Enzing, et al.
Published: (2022-08-01)

The national budget impact of managed entry agreement strategies match with high-cost drugs to maximise drug cost saving: a study protocol
by: Piyapat Owat, et al.
Published: (2024-12-01)

On the Issue of the Organizational Nature of the Grid Connection Agreement
by: M. T. Khamidullin
Published: (2019-12-01)

Using Managed Entry Agreements as an Effective Tool to Handle the Uncertainty in Health Technology Assessments
by: Vatsal Chhaya, et al.
Published: (2022-07-01)

Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choices
by: Michela Bobini, et al.
Published: (2025-02-01)

Balanced assessment systems revisited
by: Dávid Dankó, et al.
Published: (2017-01-01)

What is needed to successfully implement the EU HTA Regulation enabling broad patient access in Europe
by: Oriol Solà-Morales, et al.
Published: (2025-01-01)

Criteria adopted in different models of public healthcare systems for the evaluation of reimbursement recommendations of orphan drugs: a scoping review.
by: Arturo Felippini, et al.
Published: (2023-11-01)

DIFFERENT LEGAL APPROACHES TO THE REGULATION OF SURROGACY IN UKRAINE AND BALTIC STATES
by: Nadiia Horobets, et al.
Published: (2022-03-01)

Assessment and value of drugs: report of the focus groups from the XXII National Conference on Pharmaceuticals
by: Valentina Drago, et al.
Published: (2025-02-01)

Checklist for transferability of multidisciplinary evaluations of telemedicine
by: Anne-Kirstine Dyrvig, et al.
Published: (2012-06-01)

EUPATI Guidance for Patient Involvement in Medicines Research and Development: Health Technology Assessment
by: Amy Hunter, et al.
Published: (2018-09-01)

Multiple criteria decision analyisis for health technology assessment: scientific substantiation of criteria selection in Ukraine
by: O. B. Piniazhko, et al.
Published: (2018-08-01)

Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016
by: Julia I. Drake, et al.
Published: (2017-01-01)

Snake Oil or Super Drug: How Have Regulators and Payers Perceived New Medicines that Target Asymptomatic Conditions?
by: Brian Richard Needham
Published: (2023-11-01)

The mechanisms of entry of scientific, industrial and educational institutions in the Povolzh’e rye cluster
by: O. V. Kostenko
Published: (2017-06-01)

Access in all areas? a round up of developments in market access and health technology assessment: part 4
by: Alice Beattie, et al.
Published: (2024-04-01)

Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
by: Panos Kefalas, et al.
Published: (2018-01-01)

Usefulness of dalbavancin in early discharge and non-hospitalization. It’s time to throw your heart over the obstacle?
by: Massimo Crapis, et al.
Published: (2024-07-01)

A Proposal for Value-Based Managed Entry Agreements in an Environment of Technological Change and Economic Challenge for Publicly Funded Healthcare Systems
by: Entela Xoxi, et al.
Published: (2022-06-01)

Third-party reproduction
by: Linda Hammer Burns, et al.
Published: (2020-10-01)

Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations?
by: Virginia Ronco, et al.
Published: (2021-12-01)

Editorial for the Special Issue on “Artificial Intelligence in Health System Decision Making”
by: Mohammadreza Mobinizadeh
Published: (2023-12-01)

Health Technology Assessment (HTA) and health policy making: a narrative review
by: Anuji Upekshika Gamage, et al.
Published: (2020-11-01)

Artificial intelligence in reproductive medicine
by: O. B. Zhukov, et al.
Published: (2023-01-01)